Extragonadal germ cell tumour: lines of therapy
3 standard-of-care settings across 1 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Seminoma (mediastinal or retroperitoneal) | BEP for three cycles or EP for four; radiotherapy only for small retroperitoneal disease; PET to assess residual masses. | 81 | ||
| All comers | Non-seminoma, retroperitoneal | BEP for three or four cycles by IGCCCG risk group, then resection of residual masses over one centimetre. | 81 | ||
| IMDC risk | Non-seminoma, mediastinal (poor risk) | Four cycles of BEP or VIP, then surgery of residual disease; consider high-dose chemotherapy with autologous stem cell rescue at relapse; treat in a specialist centre. | 81 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.